Novo Nordisk and Eli Lilly have both launched oral GLP-1 weight-loss pills this year, giving millions of Americans a needle-free alternative to popular injectables like Wegovy and Zepbound. But the arrival of these new pills is not expanding employer coverage of GLP-1 drugs. In many cases, it is accelerating the retreat.
A growing share of large U.S. employers are pulling back GLP-1 weight-loss benefits, or tightening eligibility so sharply that the coverage barely functions. The reason is straightforward: the drugs cost too much, too many employees want them, and too many quit taking them before the employer sees a return on the investment.
The numbers tell the story. A Mercer survey found that nearly half of all large employers covered GLP-1 medications for weight loss in 2025. By 2026, 6% of employers with 500 or more workers had already dropped that coverage. Another 5% are planning to drop it or actively considering doing so for 2027. A separate Business Group on Health survey, reported by CNBC, found that 10% of companies currently covering GLP-1s for weight management are unlikely or very unlikely to continue doing so in 2027.
That same survey found 87% of employers expect the availability of oral GLP-1 medications to increase demand. Only 9% predict a price drop.
In other words, employers see pills making the problem worse, not better. More employees will want the drugs. The bills will keep climbing. And nobody in the boardroom expects relief.
List prices for GLP-1 obesity drugs run between $1,000 and $1,350 per month before insurance. After various discounts and rebates negotiated through pharmacy benefit managers, employers still pay a net price of roughly $569 to $664 per month per employee, according to estimates from the Institute for Clinical and Economic Review.
That is not a rounding error on a benefits budget. An NFP survey found that 51% of employers now cite GLP-1s as the single biggest driver of rising prescription drug costs. Nick Conway, president of Rx Solutions at NFP, put it bluntly:
"Employers say the rise in pharmacy costs is unsustainable."
Conway also acknowledged the bind employers face. Employees want these drugs badly, badly enough that 29% told NFP they would switch employers to get access to GLP-1 benefits. That creates a painful tug-of-war: cover the drugs and hemorrhage money, or drop them and hemorrhage talent.
The problem is not limited to small firms watching their margins. The New York Post reported that employer health insurance premiums are projected to rise 9.5% in 2026, the steepest increase since at least 2011, with GLP-1 treatments cited as a major driver. Mutual of Omaha, which employs roughly 6,300 workers, dropped GLP-1 weight-loss coverage entirely after experiencing double-digit cost growth. "We're certainly frustrated," said Steven Schlange, the company's vice president of human resources.
Health insurer Cigna has already ceased GLP-1 weight-loss coverage for its own employees, as Newsmax reported, a telling signal when even insurers decide the economics do not work.
The oral GLP-1 drugs were greeted with genuine excitement. Novo Nordisk introduced its weight-loss pill in early January. Eli Lilly's Foundayo began shipping in April. Both companies have launched direct-to-consumer pricing starting at $149 per month for the lowest doses, well below the injectable list prices.
But those consumer-facing cash prices have not translated into meaningful savings for employers. The net cost employers pay after PBM-negotiated discounts has not dropped significantly, because the pills carry list prices in the same range as injectables. Meanwhile, trials show the pills are less effective for weight loss than their injectable counterparts, raising questions about whether employers are paying nearly the same price for a weaker result.
Pharmacy benefit managers add another layer of friction. Some PBMs impose fees on employers who decline to cover the new oral options, creating pressure to add coverage even when the cost math does not improve. The recent controversy over CVS Caremark's handling of Zepbound coverage illustrates how tangled the relationship between PBMs, insurers, and patients has become.
Jeff Levin-Scherz, population health leader at WTW, acknowledged the uncertainty:
"It's still early. We don't know what's really going to happen."
He added that net prices have come down and that increased competition from additional manufacturers should continue to apply pressure. But Ben Barner, clinical pharmacy leader at Brown & Brown, indicated that meaningful competition from new manufacturers is at least a year away.
Rather than dropping GLP-1 coverage outright, many employers are restricting access. Eileen Pincay, national pharmacy practice leader at Segal, described employers tightening BMI qualification requirements, limiting coverage to diabetics only, or adding stricter behavioral management requirements before employees can access the drugs.
Some employers are shifting employees toward health reimbursement arrangements, essentially giving workers a fixed dollar amount and letting them buy the drugs directly at consumer cash prices. Eli Lilly has built an entire platform around this model. Its Lilly Employer Connect program, launched in March 2026, partners with more than 15 independent program administrators, including 9amHealth, GoodRx, and Goodpath, to offer tailored obesity coverage options for employers who want to provide access without absorbing the full insurance cost.
Novo Nordisk has a similar employer program. Both companies clearly see the writing on the wall: traditional employer insurance coverage is not going to be the primary channel for these drugs going forward. The entry of Amazon into the GLP-1 pharmacy market with aggressive pricing underscores how rapidly the distribution landscape is shifting away from conventional employer plans.
The federal government has also stepped in. CMS announced that starting July 1, GLP-1 medications will be available through Medicare for as low as $50 per month. That is good news for seniors, but it does nothing for the working-age employees whose employers are pulling back coverage. In fact, the projected cost of the Medicare GLP-1 program has raised its own set of fiscal questions.
The core tension in the GLP-1 employer coverage debate is not really about pills versus injections. It is about a fundamental mismatch between how these drugs work and how employer insurance is structured.
GLP-1 medications require long-term, often indefinite use. Patients who stop taking them typically regain weight. But employers, especially those with high employee turnover, face the prospect of paying $6,000 to $8,000 per year per employee for a drug whose benefits evaporate the moment someone leaves the company or stops the prescription. The concern about employee discontinuation is a recurring theme across every survey and every benefits consultant quoted in the available reporting.
Raymond Brown, North American clinical pharmacy leader at Mercer, captured the dilemma: employers "want their employees to be as healthy as possible" but cannot absorb the costs. That is not a failure of compassion. It is a failure of pricing.
Two pharmaceutical companies, Novo Nordisk and Eli Lilly, effectively control the entire GLP-1 weight-loss market. Until additional manufacturers bring competing products to market, employers have almost no leverage to negotiate lower prices. The FDA's moves to block compounding pharmacies from producing cheaper alternatives have further limited the options available to cost-conscious employers and patients.
Eileen Pincay offered what might be the most honest assessment of the situation:
"Eventually the prices will go down. Just not yet."
Louis Zollo, a pharmacy practice leader at Segal, explained the math to Newsmax: "Even though we have seen the unit cost come down, the patient population keeps growing." Dan Mendelson, CEO of Morgan Health, reinforced the point: "Every year there's going to be market growth. There's going to be more people taking these drugs, so on aggregate this still represents a major cost driver for employers."
The trajectory is clear. More employers will drop or restrict GLP-1 weight-loss coverage. More employees will be pushed toward direct-to-consumer cash pricing or employer-funded HRA arrangements that cap the company's exposure. The pharmaceutical companies are already building the infrastructure for that shift.
Whether prices eventually fall depends on competition, new manufacturers, new drug classes, and whether regulators allow cheaper alternatives to reach the market. Levin-Scherz expressed cautious optimism:
"The net prices of these drugs have come down, and I think there will continue to be pressure on them to come down, especially as other manufacturers' drugs get approved. That will hopefully continue to lower prices."
"Hopefully" is doing a lot of work in that sentence. For now, employers are stuck between employees who want the drugs and balance sheets that cannot support them. The pills were supposed to be the breakthrough that made GLP-1s affordable and accessible. Instead, they threaten to drive demand even higher while doing almost nothing to solve the cost problem.
When a breakthrough drug costs more than most employers can bear and more than most employees can afford on their own, it is not really a breakthrough. It is a pricing failure wearing a lab coat.